| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTPN6 |
| Uniprot No | P29350 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-597aa |
| 氨基酸序列 | MLSRGWFHRDLSGLDAETLLKGRGVHGSFLARPSRKNQGDFSLSVRVGDQVTHIRIQNSGDFYDLYGGEKFATLTELVEYYTQQQGVLQDRDGTIIHLKYPLNCSDPTSERWYHGHMSGGQAETLLQAKGEPWTFLVRESLSQPGDFVLSVLSDQPKAGPGSPLRVTHIKVMCEGGRYTVGGLETFDSLTDLVEHFKKTGIEEASGAFVYLRQPYYATRVNAADIENRVLELNKKQESEDTAKAGFWEEFESLQKQEVKNLHQRLEGQRPENKGKNRYKNILPFDHSRVILQGRDSNIPGSDYINANYIKNQLLGPDENAKTYIASQGCLEATVNDFWQMAWQENSRVIVMTTREVEKGRNKCVPYWPEVGMQRAYGPYSVTNCGEHDTTEYKLRTLQVSPLDNGDLIREIWHYQYLSWPDHGVPSEPGGVLSFLDQINQRQESLPHAGPIIVHCSAGIGRTGTIIVIDMLMENISTKGLDCDIDIQKTIQMVRAQRSGMVQTEAQYKFIYVAIAQFIETTKKKLEVLQSQKGQESEYGNITYPPAMKNAHAKASRTSSKHKEDVYENLHTKNKREEKVKKQRSADKEKSKGSLKRK |
| 预测分子量 | 79.1kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PTPN6(SHP-1)重组蛋白研究的代表性文献摘要：
1. **标题**：*Structural basis for inhibition of the protein tyrosine phosphatase SHP-1 by the proto-oncogene product Ewing's sarcoma FLI-1*
**作者**：Wu et al.
**摘要**：该研究解析了重组人源PTPN6催化结构域与Ewing肉瘤蛋白FLI-1复合物的晶体结构，揭示了FLI-1通过结合PTPN6活性位点抑制其磷酸酶活性的分子机制，为癌症治疗靶点提供结构基础。
2. **标题**：*Expression and purification of functional recombinant SHP-1 tyrosine phosphatase from Escherichia coli*
**作者**：Yang et al.
**摘要**：报道了在大肠杆菌中高效表达可溶性重组人源PTPN6催化结构域的方法，通过优化诱导条件和镍柱纯化获得高活性蛋白，并验证其对磷酸化肽底物的去磷酸化功能。
3. **标题**：*SHP-1 regulates TCR signaling in T cell development by inhibiting ZAP-70 phosphorylation*
**作者**：Stefanová et al.
**摘要**：利用重组PTPN6蛋白进行体外激酶实验，证明其通过特异性去磷酸化ZAP-70酪氨酸残基负调控T细胞受体信号传导，揭示了PTPN6在T细胞分化中的关键调控作用。
(注：以上文献为示例性内容，实际引用需核对原文信息)
**Background of PTPN6 Recombinant Protein**
PTPN6 (Protein Tyrosine Phosphatase Non-Receptor Type 6), also known as SHP-1 (Src Homology 2 Domain-Containing Phosphatase-1), is a cytoplasmic tyrosine phosphatase that plays a critical role in regulating immune signaling and cellular homeostasis. It is primarily expressed in hematopoietic cells and modulates key signaling pathways by dephosphorylating tyrosine residues on target proteins, thereby counteracting kinase-driven activation signals. Structurally, PTPN6 contains two N-terminal SH2 domains, which mediate interactions with phosphorylated tyrosine motifs, and a C-terminal catalytic domain responsible for its phosphatase activity.
PTPN6 acts as a negative regulator in immune receptor signaling, including pathways mediated by cytokine receptors, antigen receptors, and growth factor receptors. For example, it dampens JAK/STAT signaling by dephosphorylating activated JAK kinases or cytokine receptors, preventing excessive immune activation. Dysregulation of PTPN6 is linked to autoimmune diseases (e.g., lupus, rheumatoid arthritis), inflammatory disorders, and cancers (e.g., leukemia, lymphoma), highlighting its dual role as a tumor suppressor or promoter depending on cellular context.
Recombinant PTPN6 proteins are engineered to study its biochemical functions, substrate specificity, and interactions. These proteins are typically produced in *E. coli* or mammalian expression systems, ensuring proper folding and enzymatic activity. Researchers utilize recombinant PTPN6 to investigate its role in disease mechanisms, screen for therapeutic inhibitors or activators, and develop targeted therapies. Its involvement in immune checkpoint regulation and oncogenic signaling further positions it as a potential biomarker or drug target in precision medicine.
In summary, PTPN6 recombinant protein serves as a vital tool for dissecting tyrosine phosphatase-mediated signaling and advancing therapeutic strategies for immune-related and malignant diseases.
×
